Med24
metabolic-therapy 22. 7. 2026 • 2 min read • Trials (PubMed)

Gut Regulated Associations of Neuronal Signalling in High Blood Pressure (GRAINS-BP): a double-blinded randomised crossover placebo-controlled trial.

BACKGROUND: Hypertension affects 1 in 3 Australian adults and is a major contributor to stroke and myocardial infarction. Despite the availability of various medications, over 50% of patients struggle to control their blood pressure (BP) due to nonadherence, difficulty finding the right treatment, or avoidance of...

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

The Gut Regulated Associations of Neuronal Signalling in High Blood Pressure (GRAINS-BP) clinical trial investigates hypertension in adults with elevated blood pressure. The study will involve 29 participants with untreated hypertension, utilizing a double-blind, cross-over design.

Study Design and Participants

Participants will receive HAMSA/B, a high amylose maize starch enriched with acetate and butyrate, as a shake administered twice daily for 48 days. Assessments will occur at the Alfred Hospital in Melbourne, Australia, including measurement of muscle sympathetic nerve activity (MSNA) and electrocardiogram (ECG) at baseline. During the intervention period, faecal, urine, and blood samples will be collected to analyze microbiome, cardiometabolic, renal, and immune profiles.

Sponsored content

Key Outcome Measures

Statistical analyses will examine treatment effects and correlations among these profiles. The primary outcome measures change in autonomic nervous system activity. Secondary outcomes include 24-hour blood pressure, gut microbiome composition, short-chain fatty acid levels, immune cell profiles, gastrointestinal transit time, quality of life, anxiety and depression symptoms, cognitive function, gut barrier integrity, and circulating micro- and nanoplastics. MSNA and HAMSA/B are key components of this research.

Original Scientific Source
Trials (PubMed)
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Nanotechnology-Driven 18F-FDG Imaging to Understand the Change in Insulin Sensitivity: Current Evidence, Methodological Gaps, and Translational Challenges.
metabolic-therapy

Nanotechnology-Driven 18F-FDG Imaging to Understand the Change in Insulin Sensitivity: Current Evidence, Methodological Gaps, and Translational Challenges.

Insulin resistance is an important metabolic derangement contributing to the pathogenesis of type 2 diabetes, obesity, metabolic syndrome, and other chronic diseases, underlining the requirement for techniques that enable in vivo analysis of tissue-specific glucose metabolism. 18F-fluorodeoxyglucose positron emission...

10. 11. 2026 Read article →
Cardiometabolic Abnormalities among Normal-Weight Adults: Prevalence and Associated Sociodemographic and Lifestyle Factors in a Large Spanish Cohort.
metabolic-therapy

Cardiometabolic Abnormalities among Normal-Weight Adults: Prevalence and Associated Sociodemographic and Lifestyle Factors in a Large Spanish Cohort.

BACKGROUND: Although body mass index (BMI) is widely used to assess obesity-related health risks, it may fail to detect individuals with normal weight who present with significant cardiometabolic abnormalities. This phenotype, often overlooked in clinical practice, is associated with increased risk of cardiovascular...

30. 10. 2026 Read article →
Advertisement